Comments
Loading...
CytomX Therapeutics Insider Trading Activity | NASDAQ:CTMX | Benzinga
Track the latest CytomX Therapeutics insider trading activity. Stay informed on recent buys, sells, and market impact for CytomX Therapeutics stock.
What is Insider Activity?
Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide valuable insights into their confidence in the company's future performance.
What are CytomX Therapeutics Inc Insiders Doing?
Insiders have report no purchases/sales in the last 30 days.
Notable Recent Insider Buys and Sales
- On March 20, 2025, Yu-Waye Chu, the company's CHIEF MEDICAL OFFICER sold 4.03K shares for $0.6 each.
- On March 20, 2025, Christopher Ogden, the company's CHIEF FINANCIAL OFFICER sold 8.55K shares for $0.6 each.
- On March 20, 2025, Lloyd Rowland, the company's GENERAL COUNSEL sold 10.2K shares for $0.6 each.
Ownership Statistics for CytomX Therapeutics Inc
Shares Outstanding
157.544M
Insider Shares Owned
2.346M
Insider Percentage Owned
1.49%
Institutional Shares Held
13.802M
Institutional Percentage Held
8.76%
| Mar 20, 2025 | Sean A McCarthy | CEO | -37.66K | $0.60 | -$22.56K | SELL | -3.34% | 1.09M | Mar 18 | View |
| Mar 20, 2025 | Christopher Ogden | CHIEF FINANCIAL OFFICER | -8.55K | $0.60 | -$5.12K | SELL | -4.08% | 201.03K | Mar 18 | View |
| Mar 20, 2025 | Yu-Waye Chu | CHIEF MEDICAL OFFICER | -4.03K | $0.60 | -$2.41K | SELL | -2.88% | 135.72K | Mar 18 | View |
| Mar 20, 2025 | Lloyd Rowland | GENERAL COUNSEL | -10.20K | $0.60 | -$6.11K | SELL | -7.80% | 120.59K | Mar 18 | View |
| Mar 20, 2025 | Marcia Belvin | SVP, CHIEF SCIENTIFIC OFFICER | -19.51K | $0.60 | -$11.69K | SELL | -7.28% | 248.64K | Mar 18 | View |
| Aug 22, 2024 | Jeffrey B Landau | CHIEF BUSINESS OFFICER | 7.07K | $1.23 | -$5.14K | SELL-OPTIONS | 6.14% | 122.24K | Aug 20 | View |
| Aug 22, 2024 | Marcia Belvin | SVP, CHIEF SCIENTIFIC OFFICER | 7.07K | $1.23 | -$5.14K | SELL-OPTIONS | 4.19% | 175.65K | Aug 20 | View |
| Aug 22, 2024 | Lloyd Rowland | GENERAL COUNSEL | 7.07K | $1.23 | -$5.14K | SELL-OPTIONS | 5.71% | 130.80K | Aug 20 | View |
| Aug 22, 2024 | Christopher Ogden | CHIEF FINANCIAL OFFICER | 4.89K | $1.23 | -$2.44K | SELL-OPTIONS | 4.74% | 108.08K | Aug 20 | View |
| Aug 22, 2024 | Sean A McCarthy | CEO | 23.60K | $1.23 | -$17.08K | SELL-OPTIONS | 3.24% | 751.01K | Aug 20 | View |
| Mar 21, 2024 | Lloyd Rowland | GENERAL COUNSEL | -5.27K | $2.09 | -$10.99K | SELL | -4.28% | 117.73K | Mar 19 | View |
| Mar 21, 2024 | Sean A McCarthy | CEO | -20.22K | $2.09 | -$42.18K | SELL | -3.17% | 617.64K | Mar 19 | View |
| Mar 21, 2024 | Christopher Ogden | SVP, FINANCE AND ACCOUNTING | -2.97K | $2.09 | -$6.20K | SELL | -3.35% | 85.69K | Mar 19 | View |
| Mar 21, 2024 | Marcia Belvin | SVP, CHIEF SCIENTIFIC OFFICER | -12.79K | $2.09 | -$26.68K | SELL | -7.05% | 168.58K | Mar 19 | View |
| Mar 21, 2024 | Jeffrey B Landau | CHIEF BUSINESS OFFICER | -6.56K | $2.09 | -$13.69K | SELL | -5.48% | 113.24K | Mar 19 | View |
| Dec 22, 2023 | Sean A McCarthy | CEO | -13.55K | $1.38 | -$18.71K | SELL | -2.41% | 547.86K | Dec 20 | View |
| Dec 22, 2023 | Marcia Belvin | SVP, CHIEF SCIENTIFIC OFFICER | -4.08K | $1.38 | -$5.63K | SELL | -2.56% | 155.12K | Dec 20 | View |
| Dec 22, 2023 | Jeffrey B Landau | CHIEF BUSINESS OFFICER | -4.08K | $1.38 | -$5.63K | SELL | -4.34% | 89.80K | Dec 20 | View |
| Dec 22, 2023 | Lloyd Rowland | GENERAL COUNSEL | -4.08K | $1.38 | -$5.63K | SELL | -3.99% | 98.00K | Dec 20 | View |
| Dec 22, 2023 | Christopher Ogden | SVP, FINANCE AND ACCOUNTING | -1.99K | $1.38 | -$2.75K | SELL | -3.93% | 48.66K | Dec 20 | View |
| Sep 22, 2023 | Marcia Belvin | SVP, CHIEF SCIENTIFIC OFFICER | 7.13K | $1.30 | -$5.36K | GRANT | 5.06% | 147.95K | Sep 20 - Sep 22 | View |
| Sep 22, 2023 | Jeffrey B Landau | CHIEF BUSINESS OFFICER | 7.13K | $1.30 | -$5.36K | GRANT | 9.85% | 79.56K | Sep 20 - Sep 22 | View |
| Sep 22, 2023 | Sean A McCarthy | CEO | 25.40K | $1.30 | -$18.99K | GRANT | 5.09% | 523.91K | Sep 20 - Sep 22 | View |
| Sep 22, 2023 | Lloyd Rowland | GENERAL COUNSEL | 9.51K | $1.30 | -$7.14K | GRANT | 13.38% | 80.61K | Sep 20 - Sep 22 | View |
| Mar 31, 2023 | Elaine V Jones | — | 5.00K | $1.55 | $7.75K | BUY | 3521.13% | 5.14K | Mar 29 | View |
| Mar 20, 2023 | Christopher Ogden | SVP, FINANCE AND ACCOUNTING | -516.00 | $1.98 | -$1.02K | SELL | -1.35% | 37.77K | Mar 16 | View |
| Mar 20, 2023 | Carlos Campoy | CHIEF FINANCIAL OFFICER | -1.75K | $1.98 | -$3.46K | SELL | -4.37% | 38.22K | Mar 16 | View |
| Mar 20, 2023 | Sean A McCarthy | CEO | -7.12K | $1.88 | -$13.39K | SELL | -1.46% | 481.98K | Mar 16 | View |
| Mar 20, 2023 | Lloyd Rowland | GENERAL COUNSEL | -2.04K | $1.98 | -$4.03K | SELL | -2.79% | 71.09K | Mar 16 | View |
| Mar 20, 2023 | Jeffrey B Landau | CHIEF FINANCIAL OFFICER | -1.48K | $1.98 | -$2.92K | SELL | -2.00% | 72.43K | Mar 16 | View |
| Mar 20, 2023 | Amy C Peterson | EVP, CHIEF DEVELOPMENT OFFICER | -4.26K | $1.98 | -$8.42K | SELL | -6.79% | 58.43K | Mar 16 | View |
| Jul 21, 2022 | Amy C Peterson | EVP, CHIEF DEVELOPMENT OFFICER | 12.54K | $1.42 | -$10.61K | GRANT | 25.00% | 62.69K | Jul 19 - Jul 20 | View |
| Jul 21, 2022 | Jeffrey B Landau | CHIEF BUSINESS OFFICER | 7.04K | $1.42 | -$5.98K | GRANT | 26.22% | 33.91K | Jul 19 - Jul 20 | View |
| Jul 21, 2022 | Sean A McCarthy | PRESIDENT AND CEO | 25.09K | $1.42 | -$21.21K | GRANT | 6.99% | 384.10K | Jul 19 - Jul 20 | View |
| Jul 21, 2022 | Lloyd Rowland | GENERAL COUNSEL | 9.40K | $1.42 | -$7.97K | GRANT | 27.41% | 43.69K | Jul 19 - Jul 20 | View |
| Jul 21, 2022 | Alison L Hannah | CHIEF MEDICAL OFFICER | 9.40K | $1.42 | -$7.97K | GRANT | 41.77% | 31.90K | Jul 19 - Jul 20 | View |
| Jul 21, 2022 | Carlos Campoy | CHIEF FINANCIAL OFFICER | 11.05K | $1.42 | -$5.62K | GRANT | 38.21% | 39.97K | Jul 19 - Jul 20 | View |
| Jun 21, 2021 | Sean A McCarthy | PRESIDENT AND CEO | -100.00K | $7.04 | -$704.47K | SELL | -49.76% | 100.97K | Jun 16 | View |
| Apr 02, 2021 | Sean A McCarthy | PRESIDENT AND CEO | 0.00 | $4.31 | -$636.08K | SELL-OPTIONS | 0.00% | 206.89K | Mar 31 | View |
FAQ
Is insider trading legal?
Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.
What are some examples of market manipulation?
Insider trading, pump and dump schemes, front running and wash trades are all examples of market manipulation. Investors who track insider asset movement should think carefully about why these insiders are trading their stocks before moving forward.
Browse insider trades on all stocks.
